128 related articles for article (PubMed ID: 11274759)
1. Purging of myeloma cells using all-trans retinoic acid in a mouse model.
Henry JM; Morley AA; Sykes PJ
Exp Hematol; 2001 Mar; 29(3):315-21. PubMed ID: 11274759
[TBL] [Abstract][Full Text] [Related]
2. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
3. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse.
Manning LS; Berger JD; O'Donoghue HL; Sheridan GN; Claringbold PG; Turner JH
Br J Cancer; 1992 Dec; 66(6):1088-93. PubMed ID: 1457349
[TBL] [Abstract][Full Text] [Related]
4. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
5. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
6. Interaction between a murine myeloma cell line and bone marrow stromal cells.
Bradley TR; Kriegler AB; Verschoor SM; Tzelepis SM; Cooper IA
Exp Hematol; 1996 Feb; 24(2):307-9. PubMed ID: 8641357
[TBL] [Abstract][Full Text] [Related]
7. [Influence of rosiglitazone and all-trans-retinoic acid on angiogenesis and growth of myeloma xenograft in nude mice].
Huang HW; Chen P; Li BZ; Fu JX; Li J; Zhang XH; Liu R; Fan YY; Zhang H; Chow HC; Leung AY; Liang R
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):652-7. PubMed ID: 23159076
[TBL] [Abstract][Full Text] [Related]
8. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse.
Vanderkerken K; De Raeve H; Goes E; Van Meirvenne S; Radl J; Van Riet I; Thielemans K; Van Camp B
Br J Cancer; 1997; 76(4):451-60. PubMed ID: 9275021
[TBL] [Abstract][Full Text] [Related]
9. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
[TBL] [Abstract][Full Text] [Related]
10. Differential in vitro and in vivo effects of all-trans retinoic acid on the growth of human myeloma cells.
Labaume S; Chopin M; Pla M; Brouet JC
Leuk Lymphoma; 1998 Jul; 30(3-4):361-6. PubMed ID: 9713966
[TBL] [Abstract][Full Text] [Related]
11. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
[TBL] [Abstract][Full Text] [Related]
12. [Rosiglitazone and all-trans retinoic acid inhibit human myeloma cell proliferation via apoptosis signaling pathway modulation].
Huang HW; Wu DP; Chen GH; Chang HR; Chow HC; Leung AY; Liang R
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):242-6. PubMed ID: 19731824
[TBL] [Abstract][Full Text] [Related]
13. Selective in vivo growth of lymphocyte function- associated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion.
Asosingh K; Vankerkhove V; Van Riet I; Van Camp B; Vanderkerken K
Exp Hematol; 2003 Jan; 31(1):48-55. PubMed ID: 12543106
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
Yang H; Robinson SN; Nieto Y; Jones RJ; Gocke CD; Lu J; Giralt SA; Jones RB; Decker WK; Xing D; Steiner D; Champlin RE; McMannis JD; Ng J; Thomas MW; Shah N; Andersson BS; Parmar S; Shpall EJ
Cancer Res; 2011 Jul; 71(14):5040-9. PubMed ID: 21646477
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid modulates Fas antigen expression and affects cell proliferation and apoptosis in combination with anti-Fas monoclonal antibody in the human myeloma cell line, U266B1.
Okamura T; Masuda M; Arai Y; Ishida C; Shudou K; Mizoguchi H
Exp Hematol; 1998 Jun; 26(6):501-6. PubMed ID: 9620283
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells.
Otsuki T; Yata K; Sakaguchi H; Kurebayashi J; Matsuo Y; Uno M; Fujii T; Eda S; Isozaki Y; Yawata Y; Yamada O; Wada H; Sugihara T; Ueki A
Br J Haematol; 2002 Mar; 116(4):787-95. PubMed ID: 11886382
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.
Asosingh K; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
Blood; 2003 Apr; 101(8):3136-41. PubMed ID: 12480692
[TBL] [Abstract][Full Text] [Related]
19. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
20. Effects of dexamethasone, all-trans retinoic acid, vitamin D(3) and interferon-alpha on FO myeloma cells.
Ozdemir F; Esen N; Ovali E; Tekelioglu Y; Yilmaz M; Aydin F; Kavgaci H; Boruban C
Chemotherapy; 2004 Oct; 50(4):190-3. PubMed ID: 15347912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
